Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA
- SERB assumes responsibility for the commercialization of Idefirix in transplantation in the EU, UK, Switzerland, Norway, Liechtenstein, Iceland and MENA region
- The transaction significantly strengthens Hansa’s financial position and enables a robust US launch, subject to US approval of imlifidase
Lund, Sweden, July 1, 2026. Hansa Biopharma AB (“Hansa” or “the Company”) (Nasdaq Stockholm: HNSA) and SERB S.A. (“SERB”) today announced required regulatory approvals have been obtained and that the previously announced exclusive licensing transaction with SERB has closed.
